{"id":4578,"date":"2025-03-31T18:12:13","date_gmt":"2025-03-31T18:12:13","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/neomycin-sulphate-txt\/"},"modified":"2025-03-31T18:12:13","modified_gmt":"2025-03-31T18:12:13","slug":"neomycin-sulphate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/neomycin-sulphate-txt\/","title":{"rendered":"neomycin sulphate.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntibacterial agent:Bowel sterilisation before surgery Hepatic coma

DOSE IN NORMAL RENAL FUNCTION <\/H3>Bowel sterilisation: 1 g every hour for 4 hours, then 1 g every 4 hours for 2\u20133 daysHepatic coma: up to 4 g daily in divided doses usually for a maximum of 14 days

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :711.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0\u201330<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 30\u201350<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.25<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/12\u201324

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. Use with caution and monitor renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Use with caution and monitor renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Use with caution and monitor renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anticoagulants: altered INR with coumarins or phenindioneBotulinum toxin: neuromuscular block enhanced (risk of toxicity)\n
  • Ciclosporin: increased risk of nephrotoxicityCytotoxics: possibly reduced methotrexate absorption; increased risk of nephrotoxicity and possibly of ototoxicity with platinum compounds\n
  • Diuretics: increased risk of ototoxicity with loop diureticsMuscle relaxants: enhanced effects of suxamethonium and non-depolarising muscle relaxantsParasympathomimetics: antagonism of effect of neostigmine and pyridostigmine\n
  • Tacrolimus: increased risk of nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, topical

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Only 3% of an oral dose is absorbed About 97% of an orally administered dose is excreted unchanged in the faeces. Impaired GI motility may increase absorption of the drug; therefore, possible that prolonged therapy could result in ototoxicity and nephrotoxicity, particularly in patients with a degree of renal failureIf renal impairment occurs the dose should be reduced or treatment discontinuedHigh doses associated with nephrotoxicity and ototoxicityIn mild renal failure, i.e. a GFR>50 mL\/ min, the frequency should be reduced to every 6 hoursneomycin sulphate.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antibacterial agent:Bowel sterilisation before surgery Hepatic coma DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4578","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4578"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4578\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}